tozadenant
Jump to navigation
Jump to search
Indications
Dosage
Adverse effects
- dyskinesia [16-20% vs 8% for placebo]
- nausea (11-12% vs 4% for placebo)
- dizziness
Notes
- completion of phase 2 trial
More general terms
References
- ↑ Hauser RA et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: A phase 2b, double-blind, randomised trial. Lancet Neurol 2014 Aug; 13:767. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25008546